NCT03875690 2026-01-20
CORTIFRENCH
Centre Hospitalier Universitaire Dijon
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT01349842 2025-11-24
CirCé01
Institut Curie
Phase 3 Completed
NCT05040464 2025-05-28
COMET
Centre Hospitalier Universitaire, Amiens
Phase 3 Recruiting
NCT06332274 2025-05-13
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT02278887 2025-03-10
TIL
The Netherlands Cancer Institute
Phase 3 Completed
NCT03197077 2023-04-07
Elonva_IVM
Universitair Ziekenhuis Brussel
Phase 3 Completed
NCT03355820 2020-11-19
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
GlaxoSmithKline
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00929526 2016-10-20
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
GlaxoSmithKline
Phase 3 Completed
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn
NCT01209013 2012-05-08
Oedisse
Pinnacle Biologics Inc.
Phase 3 Withdrawn
NCT00957606 2011-04-13
Osteoporosis
Odense University Hospital
Phase 3 Unknown
NCT01003522 2009-10-28
RESTORE-AIR
Royal Marsden NHS Foundation Trust
Phase 3 Unknown